

Bay 59-3074

Catalog No: tcsc5806

Available Sizes

Size: 5mg

Size: 25mg

Size: 50mg

Size: 100mg

Directifications

Formula:

 $C_{18}H_{13}F_6NO_4S$

Pathway: GPCR/G Protein

Target: Cannabinoid Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 34 mg/mL (75.00 mM)

Observed Molecular Weight:

453.36

Copyright 2021 Taiclone Biotech Corp.



Product Description


Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively . Orally active CB1 agonist in vivo.

target: CB1/CB2 receptor partial agonist.

Ki: 48.3 and 45.5 nM (CB1 and CB2 receptors)

In vitro: analgesic, antihyperalgesic, and antiallodynic properties in rat models of acute and chronic pain. The reference concentration is 10 μ M. [1]

In vivo: administration of BAY 59-3074 (ED50 value: 0.41 mg/kg).Orally active CB1 agonist in vivo. [2] BAY 59-3074 (0.3-3 mg/kg, p.o.) induce antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic. Antiallodynic efficacy of BAY 59-3074 (1 mg/kg, p.o.) in the spared nerve injury model was maintained after 2 weeks of daily administration. However, tolerance developed rapidly (within 5 days) for cannabinoid-related side effect. [1] BAY 59-3074 have analgesic, antihyperalgesic, and antiallodynic properties in rat models of acute and chronic pain.[1]



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.